Hormonal Modulation in the Treatment of Breast Cancer (Q37926108)

25 August 2017

1 reference

title

Hormonal modulation in the treatment of breast cancer (English)

1 reference

25 August 2017

Hormonal Modulation in the Treatment of Breast Cancer (English)

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

11 December 2024

author name string

Kerin Adelson

1

1 reference

25 August 2017

Doris Germain

2

1 reference

25 August 2017

George Raptis

3

1 reference

25 August 2017

Noa Biran

4

1 reference

25 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21889718

11 December 2024

publication date

1 September 2011

1 reference

25 August 2017

September 2011

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21889718

full work available at URL

11 December 2024

https://api.elsevier.com/content/article/PII:S0889852911000600?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

https://api.elsevier.com/content/article/PII:S0889852911000600?httpAccept=text/plain

11 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Endocrinology and Metabolism Clinics of North America

11 December 2024

published in

1 reference

25 August 2017

volume

40

1 reference

25 August 2017

issue

3

1 reference

25 August 2017

page(s)

519-32, viii

1 reference

Biological and clinical considerations regarding the use of surgery and chemotherapy in the treatment of primary breast cancer

25 August 2017

cites work

3

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women

11 December 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

11 December 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Oophorectomy for breast cancer: history revisited.

11 December 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Adjuvant endocrine therapy for premenopausal women with early breast cancer.

11 December 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Efficacy of radiotherapy for ovarian ablation: results of a breast intergroup study

11 December 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

11 December 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Premarin in the management of metastatic breast carcinoma in post-menopausal patients

11 December 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer

11 December 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study

11 December 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

A clinical trial of megestrol acetate in advanced breast cancer

11 December 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal patients

11 December 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Megestrol acetate v tamoxifen in advanced breast cancer: a phase III trial of the Piedmont Oncology Association (POA)

11 December 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Should tamoxifen be used to treat premenopausal women with breast cancer?

11 December 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Contrasting Endocrine Activities of cis and trans Isomers in a Series of Substituted Triphenylethylenes

11 December 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

New synthetic agent for the induction of ovulation: preliminary trials in women

11 December 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

243. Antitumour activity of the antiestrogen ICI 46,474 (Tamoxifen) in the dimethylbenzanthracene (DMBA)—induced rat mammary carcinoma model

11 December 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474

11 December 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

11 December 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial

11 December 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Comparison between the Effects of Tamoxifen and Toremifene on the Uterus in Postmenopausal Breast Cancer Patients

11 December 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer

11 December 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93.

11 December 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

11 December 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

11 December 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer

11 December 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-alpha

11 December 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment

11 December 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial

11 December 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials

11 December 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer

11 December 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Fulvestrant: pharmacokinetics and pharmacology

11 December 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Fulvestrant (Faslodex) -- how to make a good drug better

11 December 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer

11 December 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

11 December 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group

11 December 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.

11 December 2024

50

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate

11 December 2024

51

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

11 December 2024

52

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

11 December 2024

53

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Letrozole for advanced breast cancer

11 December 2024

54

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

11 December 2024

55

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group

11 December 2024

56

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

11 December 2024

57

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen

11 December 2024

58

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

11 December 2024

59

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

Quality of health care delivered to adults in the United States

11 December 2024

60

1 reference

https://api.crossref.org/works/10.1016/J.ECL.2011.05.011

11 December 2024

Identifiers

1 reference

25 August 2017

1 reference